Algernon Pharmaceuticals (AGN) AI Stock Analysis

• Market Cap: C$2.56M
• Dividend Yield: N/A
• Average Volume (3M): 13.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: N/A
• EPS Growth: 64.77%
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 46,499,270
• 10 Day Avg. Volume: 14,017
• 30 Day Avg. Volume: 13,803
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.06 ▼(-3.33% Downside)

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a debt-free balance sheet. Technicals further weigh on the score as the stock trades below major moving averages with bearish momentum, while valuation is constrained by negative earnings and no dividend data.

Algernon Pharmaceuticals Business Overview & Revenue Model

Company Description

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Algernon Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products. The company focuses on repurposing existing drugs, which can streamline the approval process and reduce costs associated with drug development. Revenue is primarily generated through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its proprietary compounds once approved. Additionally, Algernon may secure funding through grants or investment in its research and development initiatives. The company's earnings are influenced by the success of its clinical trials, regulatory approvals, and the ability to establish strategic partnerships for commercialization.

Algernon Pharmaceuticals Financial Statement Overview

Summary

Algernon Pharmaceuticals is facing significant financial challenges with zero revenue and operational losses. Although the balance sheet shows no debt and a reliance on equity, cash burn remains a persistent issue. The company needs to focus on generating revenue and improving operational efficiencies.

Income Statement

The company has consistently reported zero revenue, indicating a lack of commercialized products or services. Despite a reported positive net income in the TTM (Trailing-Twelve-Months), historical data shows significant net losses, demonstrating instability. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has a strong equity position with zero debt, reflected in a Debt-to-Equity Ratio of zero. However, the shrinking asset base and equity over the years suggest potential financial strain. The Equity Ratio shows moderate reliance on equity financing.

Cash Flow

Operating cash flows have been consistently negative, indicating operational cash challenges. Free cash flow has also been negative, pointing to cash outflows exceeding cash inflows. Financing activities have been necessary to support operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-54.69K	-54.69K	-26.56K	-50.40K	-34.94K	0.00
EBITDA	-1.66M	-1.66M	-476.42K	-4.98M	-6.02M	-8.05M
Net Income	-1.72M	-1.72M	-502.98K	-6.78M	-6.05M	-7.73M
Balance Sheet
Total Assets	4.88M	4.88M	3.94M	4.19M	8.14M	10.14M
Cash, Cash Equivalents and Short-Term Investments	176.50K	176.50K	596.20K	125.08K	1.41M	2.41M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	2.18M	2.18M	1.78M	2.72M	2.52M	1.02M
Stockholders Equity	2.70M	2.70M	2.17M	1.47M	5.62M	9.12M
Cash Flow
Free Cash Flow	-1.16M	-1.16M	-2.79M	-2.61M	-3.06M	-7.95M
Operating Cash Flow	-1.16M	-1.16M	-2.71M	-2.55M	-2.91M	-7.82M
Investing Cash Flow	150.03K	150.03K	2.28M	-59.50K	-144.61K	-124.45K
Financing Cash Flow	587.31K	587.31K	901.09K	1.33M	2.06M	4.25M

Algernon Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AGN, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 20.99 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AGN.

Algernon Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLI	45 Neutral	C$2.43M	-0.96	―	―	-58.01%	29.73%
AGN	42 Neutral	C$2.56M	-0.94	―	―	―	64.77%

Algernon Pharmaceuticals Corporate Events

Algernon Health Closes $857,001 Private Placement to Advance U.S. Alzheimer’s Clinic Plans

Algernon Health has closed its non-brokered private placement financing at approximately CAD $857,001, following a fourth and final tranche that raised CAD $117,501 through the issuance of 1,678,586 units at CAD $0.07 per unit. Certain insiders participated in the final tranche, but the company relied on exemptions from formal valuation and minority approval requirements as their involvement remained below key materiality thresholds, and no finder’s fees were paid. The proceeds will be directed primarily toward advancing Algernon’s Alzheimer’s disease program, including the launch of its first U.S. Alzheimer’s clinic, as well as covering general and administrative expenses and working capital, potentially strengthening its position in the emerging neuroimaging and early-detection market for neurodegenerative disorders.

Algernon Health Boosts Private Placement to $750,000 to Advance Alzheimer’s Imaging Clinics

Algernon Health has upsized its non-brokered private placement financing to C$750,000 and closed a third tranche, raising C$352,500 from the sale of 5,035,714 units at C$0.07 each, bringing total gross proceeds from all tranches to C$739,500. The company plans to use the funds to advance its Alzheimer’s disease program, including the launch of its first U.S. Alzheimer’s clinic, and to support general and administrative expenses and working capital, underlining its push to build out a North American neuroimaging clinic network focused on brain-specific PET scanning services.

Algernon Health Secures CAD $210,000 in Private Placement to Boost Alzheimer’s Program

Algernon Health Inc. announced the closing of the second tranche of its non-brokered private placement, raising CAD $210,000 from the sale of 3,000,000 units. The funds will support the advancement of its Alzheimer’s Disease program, including the opening of its first U.S. clinic, and cover general administrative expenses and working capital. This move underscores Algernon’s commitment to expanding its presence in the neuroimaging sector, potentially enhancing its market position and offering stakeholders promising growth opportunities.

Algernon Pharmaceuticals Partners with AMI for U.S. Neuroimaging Clinics

Algernon Pharmaceuticals has announced a strategic partnership with American Molecular Imaging (AMI) to enhance its planned U.S. neuroimaging clinics. This agreement involves AMI providing exclusive radiology reading services and a $500,000 investment to support Algernon’s initiative. The collaboration aims to deliver high-quality PET scan interpretations for conditions like Alzheimer’s Disease, positioning Algernon as a leader in neuroimaging. This move is part of Algernon’s broader strategy to expand its presence in the U.S. healthcare market, supported by recent equipment acquisitions and planned clinic openings.

Algernon Health Closes First Tranche of Private Placement Financing

Algernon Health has successfully closed the first tranche of its non-brokered private placement, raising CAD $177,000. The funds will be used to advance its Alzheimer’s Disease program, including opening its first U.S. clinic. The participation of company insiders in this tranche is considered a related party transaction but does not require additional shareholder approval. The company anticipates closing additional tranches by December 1, 2025, and the securities will be subject to a statutory hold period under Canadian law.

Algernon Health Announces Private Placement and Share Structure Alteration

Algernon Health Inc. has announced a non-brokered private placement to raise $500,000 through the issuance of units consisting of common shares and warrants. The funds will be used to advance its Alzheimer’s Disease program, including the opening of its first U.S. brain-specific neuroimaging clinic. Additionally, the company has converted subscription receipts into preferred shares and warrants, following shareholder approval to alter its share structure. This strategic move aims to bolster Algernon’s market position in the healthcare sector, particularly in Alzheimer’s early detection.

Algernon Pharmaceuticals Rebrands as Algernon Health to Focus on Alzheimer’s Diagnostics

Algernon Pharmaceuticals has officially changed its name to Algernon Health, reflecting its strategic shift towards the Alzheimer’s Disease diagnostic market. The company plans to establish specialized neuroimaging clinics across North America, featuring advanced PET scanning technology for early detection of Alzheimer’s, supported by a recent equipment order and financing agreement with Catalyst MedTech. This move underscores Algernon’s commitment to evolving as a consumer-facing healthcare brand, while continuing its involvement in psychedelic research and drug development through its subsidiaries.